Loading...
Loading...
Analysts at Jefferies upgraded
Supernus Pharmaceuticals IncSUPN from Hold to Buy.
The price target for Supernus Pharmaceuticals has been raised from $11.00 to $18.00.
Supernus Pharmaceuticals shares have gained 51.32 percent over the past 52 weeks, while the S&P 500 index has surged 7.19 percent in the same period.
Supernus Pharmaceuticals' shares fell 5.27 percent to close at $16.01 yesterday.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
We simplify the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in